Antonio Gasbarrini to Irritable Bowel Syndrome
This is a "connection" page, showing publications Antonio Gasbarrini has written about Irritable Bowel Syndrome.
Connection Strength
2.412
-
Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time? Dig Dis Sci. 2017 09; 62(9):2220-2222.
Score: 0.570
-
Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders. Dig Dis. 2018; 36(1):56-65.
Score: 0.564
-
Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome? World J Gastroenterol. 2016 Dec 14; 22(46):10198-10209.
Score: 0.542
-
Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005 Dec; 22(11-12):1157-60.
Score: 0.252
-
Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci. 2019 Apr; 23(7):2986-3000.
Score: 0.159
-
New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. Dig Liver Dis. 2018 08; 50(8):741-749.
Score: 0.149
-
The gut microbiota: its anatomy and physiology over a lifetime. Minerva Gastroenterol Dietol. 2017 Dec; 63(4):329-336.
Score: 0.139
-
Fecal microbiota transplantation: past, present and future perspectives. Minerva Gastroenterol Dietol. 2017 Dec; 63(4):420-430.
Score: 0.036